Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

NCT04096417 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT04096417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04096417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2020
Completion date
December 1, 2025
Enrollment
14 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr1 gene amplification, fgfr1 gene mutation, fgfr1 gene translocation, fgfr2 gene amplification, fgfr2 gene mutation, fgfr2 gene translocation, fgfr3 gene amplification, fgfr3 gene mutation, fgfr3 gene translocation, metastatic colorectal carcinoma, stage iii colorectal cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiic colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8, unresectable colorectal carcinoma